Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...

FDA has announced the approval of LIB Therapeutics’ Lerochol (lerodalcibep-liga) for subcutaneous (SC) use as an adjunct to ...

Per the terms of the agreement, Sobi is expected to pay upwards of $950 million upfront in cash to acquire Arthrosi.The deal ...

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...

The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...

The collaboration agreement joins Relation’s AI-powered drug discovery platform and human data generation capabilities with ...

Lilly’s first Phase III results for retatrutide show unprecedented weight loss and marked reductions in osteoarthritis pain, ...

Pfizer announced it has entered into an exclusive global collaboration and license agreement with Chongqing Yao ...

M&A in biopharma is shaped by policy uncertainties, tariffs, and potential marketing rule changes, influencing strategic ...

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...

OTR Therapeutics and Zealand Pharma collaborate to develop novel metabolic disease treatments, with a potential deal value of ...

PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of ...